Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Misses Expectations By $0.05 EPS

by · The Cerbat Gem

Pyxis Oncology (NASDAQ:PYXS – Get Free Report) posted its earnings results on Thursday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05), Zacks reports.

Pyxis Oncology Stock Up 1.5%

NASDAQ:PYXS traded up $0.04 during midday trading on Friday, reaching $3.06. The stock had a trading volume of 417,197 shares, compared to its average volume of 862,363. The stock has a market cap of $193.53 million, a P/E ratio of -2.32 and a beta of 1.31. The firm has a fifty day simple moving average of $2.53 and a two-hundred day simple moving average of $1.96. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55.

Institutional Trading of Pyxis Oncology

Hedge funds have recently made changes to their positions in the company. XTX Topco Ltd increased its stake in shares of Pyxis Oncology by 1,533.0% during the fourth quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after acquiring an additional 271,334 shares during the period. Toronto Dominion Bank purchased a new position in Pyxis Oncology during the fourth quarter worth about $86,000. Quadrature Capital Ltd acquired a new stake in Pyxis Oncology in the fourth quarter valued at about $116,000. Maia Wealth LLC acquired a new stake in Pyxis Oncology in the fourth quarter valued at about $25,000. Finally, Engineers Gate Manager LP purchased a new stake in Pyxis Oncology in the 4th quarter valued at approximately $26,000. Institutional investors and hedge funds own 39.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on PYXS shares. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings lowered shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wells Fargo & Company started coverage on shares of Pyxis Oncology in a research report on Monday, August 3rd. They issued an “overweight” rating and a $12.00 price target for the company. Wedbush began coverage on shares of Pyxis Oncology in a research note on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price target for the company. Finally, Leerink Partners lowered their price objective on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, July 2nd. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

View Our Latest Stock Analysis on PYXS

Pyxis Oncology Company Profile

(Get Free Report)

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

Featured Stories